Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Chinese PLA General Hospital
University of Washington
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
University of Chicago
St. Jude Children's Research Hospital
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital
Baptist Health South Florida
Fred Hutchinson Cancer Center
Medical University of South Carolina
Henry Ford Health System
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dartmouth-Hitchcock Medical Center
Essen Biotech
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Mayo Clinic
St. Jude Children's Research Hospital
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Ohio State University Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Thomas Jefferson University
City of Hope Medical Center
University of Michigan Rogel Cancer Center
Roswell Park Cancer Institute
Masonic Cancer Center, University of Minnesota
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
University of California, San Francisco
University of Chicago
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Ruijin Hospital